The only targeted therapy designed for potent and selective inhibition of KIT D816V1–3

Explore the information below about Indolent Systemic Mastocytosis (ISM), Advanced Systemic Mastocytosis (SM) and AYVAKYT

Drawing of a fictional patient with skin lesions

ISM

What is ISM and what is the disease burden?

Drawing of a fictional patient’s medical file in a folder

Advanced SM

What is Advanced SM and how can it impact my patients?

Drawing of a clipboard with the AYVAKYT logo

About AYVAKYT

Discover how AYVAKYT works

Drawing of a fictional HCP with a graph

Clinical Trials

Learn about the efficacy and safety of AYVAKYT evaluated in the key trials: PIONEER trial in ISM and PATHFINDER trial in Advanced SM

Drawing of a pill being put in a hand

Dosing

Learn how to prepare and initiate patients with ISM and Advanced SM on AYVAKYT

Drawing of three fictional patients

Patient Profiles

Explore results in hypothetical patients taking AYVAKYT for Advanced SM

Indications1

Indolent Systemic Mastocytosis (ISM)

AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment

Advanced Systemic Mastocytosis (SM)

AYVAKYT® (avapritinib) is indicated as monotherapy for the treatment of adult patients with aggressive SM (ASM), SM with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy

Drawing of a pill being put in a hand

AYVAKYT is not recommended for the treatment of patients with Advanced SM with platelet counts of <50 x 109/L

Please see the Summary of Product Characteristics (SmPC) and other resources here

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the product SmPC for how to report adverse reactions.

References

  1. AYVAKYT® (avapritinib). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Accessed February 2024.
  2. Gotlib J, et al. Nat Med. 2021;27(12):2192–2199.
  3. Gotlib J, et al. NEJM Evid. 2023;2(6):EVIDoa2200339.

We use cookies that are strictly necessary to operate this website. We also use optional cookies to improve your accessibility to our website and its functionality, to analyse and track your use of our website, and to give you the best possible user experience. By clicking on the “Reject All Cookies” button, you understand that strictly necessary cookies will continue to be deployed for the operation of this website. For more detailed information on our use of cookies on this website, please read our Cookie Policy, which also explains how to customise your cookies settings. You can also “Accept All Cookies” or customise your cookies settings by clicking on the buttons provided below. Click “Cookie Settings” to update your personal cookie preferences or review our Privacy Policy.

To top